Concord News Now

DelveInsight’s, “Influenza Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Takeaways from the Influenza Pipeline Report

• DelveInsight’s influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for influenza treatment.
• Leading influenza companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others are evaluating novel antiviral influenza drugs candidate to improve the treatment landscape.
• Key influenza pipeline therapies in various stages of development include mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, DAS181, ALVR106, OVX836, VIR-2482, POLB 001, CD388, CT-P27, KD-404, AVA2300, CVSQIV, GSK3206641A, UniFlu, CC-42344, AV5080, mRNA-1073, UFluA, PF-07852352, GP681, ZSP1273, Sing2016, BW-1014, AVM0703, DAS181, HNC042, HEC116094, Adjuvanted Cell Culture Influenza Vaccine (aQIVc), NanoFlu, MT-8972, MT-7529, MT-2654, PrEP-001,GSK4382276A, mRNA Influenza Vaccine, LUNAR-FLU, M–001, Adintrevimab, PDS0202, Neumifil, Influenza vaccine, ETH47, GC3114A,  and others.
• mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.
• SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. 

Request a sample and discover the recent advances in Influenza @ Influenza Pipeline Outlook

Influenza Overview

Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality. The CDC documented that seasonal influenza was responsible for 24,000 to 62,000 deaths during the 2019-2020 season. Information used to generate influenza in-season burden estimates were too low during the 2020-2021 season to provide an estimate. Mortality was highest in infants and elderly persons. Influenza traditionally has been diagnosed on the basis of clinical criteria, but rapid diagnostic tests, which have a high degree of specificity but only moderate sensitivity, are becoming more widely used. The gold standard for diagnosing influenza A and B is a viral culture of nasopharyngeal samples or throat samples.

In elderly or high-risk patients with pulmonary symptoms, perform chest radiography to exclude pneumonia. Prevention of influenza is the most effective management strategy. Influenza A and B vaccine is administered each year before flu season. The CDC analyzes the vaccine subtypes each year and makes any necessary changes for the coming season on the basis of worldwide trends. Traditionally, the vaccine was trivalent (ie, designed to provide protection against three viral subtypes, generally an A-H1, an A-H3, and a B). The first quadrivalent vaccines, which provide coverage against an additional influenza B subtype, were approved in 2012 and were made available for the 2013-2014 flu season. For the 2021-2022 influenza season, all flu vaccines are expected to be quadrivalent.

Latest Breakthroughs and Developments in the Influenza Treatment Landscape

• In July 2022, Emergex Vaccines Holding Limited through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announced the manufacture of its universal/pandemic influenza vaccine, ready for Phase I clinical trials.
• CureVac has dosed the first participant in a Phase I study of the modified influenza vaccine candidate FLU SV mRNA, developed in collaboration with GSK. The study follows the start of a Phase I study in February 2022 to evaluate an unmodified, multivalent influenza vaccine candidate, CVSQIV, at clinical sites in Panama. Data from both studies are expected to be reported as a combined data set.
• In June 2022, Moderna, Inc. announced the first participants have been dosed in a Phase III study of the Company’s seasonal influenza vaccine candidate (mRNA-1010). The trial is expected to enroll approximately 6,000 adults in Southern Hemisphere countries. This Phase III randomized, observer-blind study is designed to evaluate the safety and immunological non-inferiority of mRNA-1010 to a licensed seasonal influenza vaccine in adults 18 years and older.
• In April 2022, Novavax, Inc. announced initial results from the Phase I/II clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC combines Novavax’ COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate. The CIC trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic.
• In April 2022, Osivax, announced the Phase IIa results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, Double-Blind, Reference-Controlled, Phase IIa Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine” in the journal Frontiers in Immunology. Developed using Osivax’ proprietary self-assembling nanoparticle technology, OVX836 targets an internal nucleoprotein (NP), a highly conserved antigen that is less susceptible to the constant mutations of surface antigens of the influenza virus.
• BioNTech is collaborating with Pfizer to develop an influenza vaccine based on BioNTech’s suite of mRNA platforms. In July 2022, data were reported from the Phase II expansion study of BNT161 in subjects 65 years of age and older showing first evidence of substantial induction of strain specific CD4+ and CD8+ responses. The GMFR was higher compared to the control quadrivalent influenza vaccine for both CD4+ and CD8+ strain specific T cell responses. Based on these encouraging T cell responses and observed seroconversion, a Phase III study of the quadrivalent modified mRNA influenza vaccine is planned to initiate in the second half of 2022.
• In May 2022, Blue Water Vaccines announced a collaboration with the multidisciplinary Center for R&D in Immunobiologics, an initiative of Instituto Butantan , for the development of BWV’s universal influenza candidate, BWV-101, in Brazil. Butantan is the largest flu vaccine manufacturer in the Southern Hemisphere, with 100% of influenza vaccine doses used by the Brazilian Ministry of Health manufactured at Butantan.

Influenza Pipeline Insight Report

The Influenza Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Influenza, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Influenza Pipeline Landscape.

Influenza Emerging Drugs

• mRNA-1010: Moderna
• SAB-176: SAB Biotherapeutics
• INNA-051: ENA Respiratory Pty Ltd
• CODA-VAX H1N1: Codagenix
• ALVR106: AlloVir

Influenza Pipeline Therapeutics Analysis

There are approx. 120+ key companies which are developing therapies for Influenza. The companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.

Learn more about the novel and emerging influenza pipeline therapies @ Influenza Clinical Trials

Influenza Pipeline Analysis Report

• The report provides detailed insights about emerging therapies for Influenza treatment and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Influenza Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Influenza market.

The Influenza Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.

Scope of the Influenza Pipeline Report

• Coverage: Global
• Influenza Pipeline By Product Type: Mono, Combination, Mono/Combination
• Influenza Pipeline By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Influenza Pipeline By Route of Administration: Inhalation, Intranasal, Parenteral, Oral, Intravenous, Subcutaneous, Intramuscular
• Influenza Pipeline By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
• Influenza Pipeline By Mechanism of Action: Immunostimulants, Toll like receptor 2 agonists, Toll like receptor 6 agonists, Immunologic cytotoxicity, T lymphocyte replacements, Influenza virus PB2 protein inhibitors, Endonuclease inhibitor, DNA-directed RNA polymerase inhibitor, Neuraminidase inhibitor, RNA synthesis inhibitor.
• Key Influenza Companies: Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others
• Key Influenza Pipeline Therapies: mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, DAS181, ALVR106, OVX836, VIR-2482, POLB 001, CD388, CT-P27, KD-404, AVA2300, CVSQIV, GSK3206641A, UniFlu, CC-42344, AV5080, mRNA-1073, UFluA, PF-07852352, GP681, ZSP1273, Sing2016, BW-1014, AVM0703, DAS181, HNC042, HEC116094, Adjuvanted Cell Culture Influenza Vaccine (aQIVc), NanoFlu, MT-8972, MT-7529, MT-2654, PrEP-001,GSK4382276A, mRNA Influenza Vaccine, LUNAR-FLU, M–001, Adintrevimab, PDS0202, Neumifil, Influenza vaccine, ETH47, GC3114A, and others.

Dive deep into rich insights for Influenza Pipeline Assessment, Visit @ Influenza Treatment

Table of content

1. Introduction
2. Executive Summary
3. Influenza: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Influenza – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. mRNA-1010: Moderna
9. Mid Stage Products (Phase II)
10. INNA-051: ENA Respiratory Pty Ltd
11. Early Stage Products (Phase I)
12. CODA-VAX H1N1: Codagenix
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Influenza Key Companies
17. Influenza Key Products
18. Influenza- Unmet Needs
19. Influenza- Market Drivers and Barriers
20. Influenza- Future Perspectives and Conclusion
21. Influenza Analyst Views
22. Influenza Key Companies
23. Appendix

For further information on the Influenza Pipeline therapeutics, reach out @ Influenza Drugs

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/